Literature DB >> 17219276

Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size.

Y Tsunezuka1, Y Shimizu, N Tanaka, T Takayanagi, M Kawano.   

Abstract

BACKGROUND: F-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) scanning has become a critically important tool in diagnosis and management of non-small-cell lung cancer. However, the effectiveness of (18)F-FDG-PET as a diagnostic tool for small-sized lung cancer is controversial. The purpose of this study was to examine the accuracy of( 18)F-FDG-PET in relation to Noguchi's classification in the diagnosis of small peripheral non-small-cell lung cancer.
METHODS: Between January 2003 and April 2006, 150 patients with peripheral lung lesions who were undergoing chest computed tomography (CT),( 18)F-FDG-PET, and operation were analyzed.
RESULTS: Eighty-three patients had malignant lesions, and 67 patients had benign lesions. PET had a sensitivity, specificity, positive predictive value, and negative predictive value of 75.9%, 64.1%, 72.4%, and 68.3%, respectively. In 37 patients with peripheral lung cancer measuring 2.0 cm or less in the greatest diameter, the sensitivity was 51.4% and the specificity was 51.9%. Among them, all 4 cases of Noguchi type A adenocarcinoma [localized bronchioloalveolar carcinoma (LBAC)], 4 of 5 type B and 8 of 17 type C were false negative, while 9 of 11 (81.8%) types D, E, and F (invasive carcinomas without a BAC component) were true positive.
CONCLUSION: The accuracy of( 18)F-FDG-PET is generally low in distinguishing malignancy from benign lesions in small lesions (<2.0-cm diameter). The significance of PET as a diagnostic tool is small, especially when the tumor has a ground-glass component at a high rate. The sensitivity of PET is high in small invasive carcinomas without a BAC component, but it is difficult to distinguish carcinoma from benign tumor from its image.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17219276     DOI: 10.1007/s00268-006-0475-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  12 in total

1.  False-positive and true-negative hilar and mediastinal lymph nodes on FDG-PET--radiological-pathological correlation.

Authors:  Norio Shiraki; Masaki Hara; Hiroyuki Ogino; Yuta Shibamoto; Akihiko Iida; Tsuneo Tamaki; Takayuki Murase; Tadaaki Eimoto
Journal:  Ann Nucl Med       Date:  2004-02       Impact factor: 2.668

2.  Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors.

Authors:  Jason A Zell; S-H Ignatius Ou; Argyrios Ziogas; Hoda Anton-Culver
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

3.  Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis.

Authors:  Haruhisa Matsuguma; Kohei Yokoi; Masaki Anraku; Tetsuro Kondo; Yukari Kamiyama; Kiyoshi Mori; Keigo Tominaga; Yukio Tsuura; Satoshi Honjo
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

4.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.

Authors:  Robert James Cerfolio; Buddhiwardhani Ojha; Ayesha S Bryant; Vanguru Raghuveer; James M Mountz; Alfred A Bartolucci
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

5.  Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.

Authors:  Jun Konishi; Koichi Yamazaki; Eriko Tsukamoto; Nagara Tamaki; Yuya Onodera; Toshiyuki Otake; Toshiaki Morikawa; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Respiration       Date:  2003 Sep-Oct       Impact factor: 3.580

6.  Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.

Authors:  Yaichiro Hashimoto; Tetsuya Tsujikawa; Chisato Kondo; Masako Maki; Mitsuru Momose; Atsushi Nagai; Takamasa Ohnuki; Toshio Nishikawa; Kiyoko Kusakabe
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

7.  Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.

Authors:  Cecelia S Yap; Johannes Czernin; Michael C Fishbein; Robert B Cameron; Christiaan Schiepers; Michael E Phelps; Wolfgang A Weber
Journal:  Chest       Date:  2006-02       Impact factor: 9.410

8.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis.

Authors:  M Noguchi; A Morikawa; M Kawasaki; Y Matsuno; T Yamada; S Hirohashi; H Kondo; Y Shimosato
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

9.  FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?

Authors:  Cecelia S Yap; Christiaan Schiepers; Michael C Fishbein; Michael E Phelps; Johannes Czernin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-04       Impact factor: 9.236

10.  The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma.

Authors:  Yasuhisa Ohde; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Kenro Takahashi; Kenji Suzuki; Kazuya Takamochi; Tomoyuki Yokose; Yutaka Nishiwaki
Journal:  Lung Cancer       Date:  2003-12       Impact factor: 5.705

View more
  9 in total

1.  Peripheral blood telomere alterations in ground glass opacity (GGO) lesions may suggest malignancy.

Authors:  Matthew Koslow; David Shitrit; Lilach Israeli-Shani; Orit Uziel; Einat Beery; Alexandra Osadchy; Yael Refaely; Gali Epstein Shochet; Aliza Amiel
Journal:  Thorac Cancer       Date:  2019-03-12       Impact factor: 3.500

Review 2.  Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.

Authors:  Stephen A Deppen; Jeffrey D Blume; Clark D Kensinger; Ashley M Morgan; Melinda C Aldrich; Pierre P Massion; Ronald C Walker; Melissa L McPheeters; Joe B Putnam; Eric L Grogan
Journal:  JAMA       Date:  2014-09-24       Impact factor: 56.272

3.  Pre-operative CT localization for patients with subsolid opacities expecting video-assisted thoracoscopic surgery-single center experience of fluorescent iodized emulsion and hook-wire localization technique.

Authors:  Allen Li; S Chan; K H Thung
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

4.  Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT.

Authors:  Hu-bing Wu; Lijuan Wang; Quan-shi Wang; Yan-jian Han; Hong-sheng Li; Wen-lan Zhou; Ying Tian
Journal:  Biomed Res Int       Date:  2015-03-24       Impact factor: 3.411

5.  A comparison of two commercial volumetry software programs in the analysis of pulmonary ground-glass nodules: segmentation capability and measurement accuracy.

Authors:  Hyungjin Kim; Chang Min Park; Sang Min Lee; Hyun-Ju Lee; Jin Mo Goo
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

6.  Assessing the Blood Supply Status of the Focal Ground-Glass Opacity in Lungs Using Spectral Computed Tomography.

Authors:  Guanfu Liu; Mengying Li; Guosheng Li; Zhiyong Li; Ailian Liu; Renwang Pu; Huizhi Cao; Yijun Liu
Journal:  Korean J Radiol       Date:  2018-01-02       Impact factor: 3.500

7.  [Three-dimensional Mass Measurement of Subsolid Pulmonary Nodules on Chest CT: Intra and Inter-observer Variability].

Authors:  Huiting Liu; Ying Wang; Lei Feng; Tielian Yu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-05

Review 8.  Low-dose CT: technique, reading methods and image interpretation.

Authors:  Cristiano Rampinelli; Daniela Origgi; Massimo Bellomi
Journal:  Cancer Imaging       Date:  2013-02-08       Impact factor: 3.909

9.  Evaluation of pure ground glass pulmonary nodule: a case report.

Authors:  Ning Jin; Peter J Sloane
Journal:  J Community Hosp Intern Med Perspect       Date:  2014-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.